Piper Jaffray Reiterates Overweight and PT of $20 on DexCom

by Emily Austin, Benzinga Staff Writer

June 27, 2011 6:18 AM | 14 seconds read | Make a Comment

Piper Jaffray reiterated its Overweight rating on DexCom

DXCM

. At the same time, Piper Jaffray left its price target on the company's stock unchanged at $20. On Friday, DexCom lost 0.54% of its value to end the week at $14.60.

Market News and Data brought to you by Benzinga APIs

Posted In: Reiteration Analyst Ratings dexcom Health Care Health Care Equipment Piper Jaffray

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Piper Jaffray Reiterates Overweight and PT of $20 on DexCom